Understanding the Results of SGLT2 Inhibitors Heart Failure Trials
Saturday, December 5th: 1:30 – 3:30 pm
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel oral antidiabetic drugs to lower plasma glucose levels. A growing body of evidence demonstrates that these agents have beneficial effects on both CV and kidney outcomes. Despite this, questions remain, particularly around interpretation of potentially discrepant results across heart failure (HF) trials. Are all agents created equal for patients with HF? Are the benefits a class effect? Do individual agents have different effects on different endpoints? How do I choose which agent to use?
This session is chaired by Dr. Ileana L. Piña from the Albert Einstein College of Medicine in the Bronx, NY, USA, and Dr. Milton Packer, the Distinguished Scholar in Cardiovascular Science from the Baylor University Medical Center in Dallas, TX, USA. As the principal investigator on the EMPEROR-Reduced Trial, Dr. Packer is sure to have strong opinions on this topic, and you can count on a lively discussion.
This session will take an in-depth look at the individual SGLT2i HFrEF trials as well as the results of meta-analyses. Every angle will be explored from hard CV and renal outcomes to quality of life, and safety considerations. We will provide insight into the mechanism of effects, and look at the results from a statistical point of view.
Joining our co-chairs are: Faiez Zannad (Nancy, FRA), Stefan Anker (Berlin, GER), Javed Butler (Jacksonville, USA), Joao Ferreira (Nancy, FRA), Gerasimos Filippatos (Athens, GRE), Milton Packer (Dallas), and Stuart Pocock (London, GBR).
Additional clinical and research experts will be participating in a moderated, multi-stakeholder, expert panel debate, along with representatives from the pharmaceutical industry and regulatory bodies. If this is an area where you still have questions around the use of these agents, this session will allay any doubts you may have around using these agents, and put your fears to rest once and for all.